DiaMedica Therapeutics Inc.
DMAC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001401040
No open-market purchases or sales by DiaMedica Therapeutics Inc. insiders were filed in the last 90 days; 88 institutions reported holding it in 13F filings for Q2 2026, worth $87.8M in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding DiaMedica Therapeutics Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 34 | 28 | −6 |
| Shares | 4.01M | 3.67M | −336.6K (−8.4%) |
| Value | $10.0M | $7.42M | −$2.60M (−26.0%) |
New holders (1)
Institutions that held DiaMedica Therapeutics Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Cantor Fitzgerald, L. P. | 14,691 | $30.0K | 0.00% |
Sold out (7)
Institutions that held DiaMedica Therapeutics Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Ikarian Capital, LLC | 221,252 | $553.0K |
| Boothbay Fund Management, LLC | 20,603 | $52.0K |
| Susquehanna International Group, LLP | 16,324 | $41.0K |
| Sandy Cove Advisors, LLC | 1,200 | $3.00K |
| Citigroup Inc | 273 | $1.00K |
| Group One Trading, L.P. | 20 | $0 |
| FinTrust Capital Advisors, LLC | 75 | $0 |